

**ADVANCED DRY, AGE-RELATED MACULAR DEGENERATION
PFIZER PHASE 1 STUDY**

STUDY ARM: Infusion with escalating doses of RN6G administered monthly with intent to halt progression of dry, age-related macular degeneration (AMD).

Study duration: Approximately 9 months

General Inclusion Criteria

Patients must meet the following criteria for study entry:

- Age between 60 to 85 years old. If you are a woman, you must no longer be able to have children.**
- Acceptable medical history and acceptable results of your physical examination, neurological examination, ECG, MRI, and blood and urine tests.**
- Advanced, dry AMD or geographic atrophy in at least one eye.**
- Patients must not have had a significant allergic reaction to any monoclonal antibodies.**
- Patients must not participate in any other drug study for at least 30 days before the start of this study or at any time during the study.**
- Patients must not donate blood at any time during this study.**
- Patients must not be on medications that are known to affect your eyes, on steroids for active inflammatory problems or any medication where the dosage is changed frequently.**
- Patients must have good vein access.**